Sanolium AB interim report, January - March 2021
Revenue amounted to 206.7(177.9) MSEK in the first quarter, representing a growth of 16.2%. Adjusted EBITDA amounted to 52.3(49.6)MSEK, representing a growth of 5.4%. Revenue recognition is negatively affected by the Covid-19 situation.Revenue in the first quarter amounted to 206.7 (177.9) MSEK, representing a growth of 16.2%. Support and maintenance fees constitute the largest share of the revenue. License revenue and Professional Services revenue are attributable to the development of the existing product as well as the Sussa project. Adjusted EBITDA in the first quarter amounted to